Humoral response and safety of the BNT162b2 and mRNA-1273 COVID-19 vaccines in allogeneic hematopoietic stem cell transplant recipients: An observational study.
Allogeneic
COVID-19
SARS-CoV-2
Transplantation
Vaccine
Journal
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
ISSN: 1437-7780
Titre abrégé: J Infect Chemother
Pays: Netherlands
ID NLM: 9608375
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
05
09
2022
revised:
18
11
2022
accepted:
21
11
2022
pubmed:
29
11
2022
medline:
31
1
2023
entrez:
28
11
2022
Statut:
ppublish
Résumé
The effectiveness of mRNA COVID-19 vaccines and the optimal timing of vaccine administration in allogeneic hematopoietic stem cell transplantation (Allo-HSCT) recipients remains inadequately investigated. We examine the effectiveness and safety of mRNA COVID-19 vaccines in allo-HSCT recipients. This prospective observational study included 44 allo-HSCT recipients and 38 healthy volunteers. The proportion of subjects acquiring anti-S1 IgG antibodies were considered as the primary endpoint. The occurrence of adverse events after vaccination and objective deterioration of chronic graft-versus-host disease (GVHD) were defined as secondary endpoints. In addition, we compared the geometric mean titers (GMT) of anti-S1 antibody titers in subgroups based on time interval between transplantation and vaccination. A humoral response to the vaccine was evident in 40 (91%) patients and all 38 healthy controls. The GMT of anti-S1 titers in patients and healthy controls were 277 (95% confidence interval [CI]: 120-643) BAU/mL and 532 (95% CI 400-708) BAU/mL, respectively. (p = 0.603). A short time interval between transplantation and vaccination (≤6 months) was associated with low anti-S1 IgG antibody titers. No serious adverse events and deterioration of chronic GVHD were observed. Only one case of new development of mild chronic GVHD was recorded. Messenger RNA COVID-19 vaccines induce humoral responses in allo-HSCT recipients and can be administered safely.
Sections du résumé
BACKGROUND
BACKGROUND
The effectiveness of mRNA COVID-19 vaccines and the optimal timing of vaccine administration in allogeneic hematopoietic stem cell transplantation (Allo-HSCT) recipients remains inadequately investigated. We examine the effectiveness and safety of mRNA COVID-19 vaccines in allo-HSCT recipients.
METHOD
METHODS
This prospective observational study included 44 allo-HSCT recipients and 38 healthy volunteers. The proportion of subjects acquiring anti-S1 IgG antibodies were considered as the primary endpoint. The occurrence of adverse events after vaccination and objective deterioration of chronic graft-versus-host disease (GVHD) were defined as secondary endpoints. In addition, we compared the geometric mean titers (GMT) of anti-S1 antibody titers in subgroups based on time interval between transplantation and vaccination.
RESULTS
RESULTS
A humoral response to the vaccine was evident in 40 (91%) patients and all 38 healthy controls. The GMT of anti-S1 titers in patients and healthy controls were 277 (95% confidence interval [CI]: 120-643) BAU/mL and 532 (95% CI 400-708) BAU/mL, respectively. (p = 0.603). A short time interval between transplantation and vaccination (≤6 months) was associated with low anti-S1 IgG antibody titers. No serious adverse events and deterioration of chronic GVHD were observed. Only one case of new development of mild chronic GVHD was recorded.
CONCLUSION
CONCLUSIONS
Messenger RNA COVID-19 vaccines induce humoral responses in allo-HSCT recipients and can be administered safely.
Identifiants
pubmed: 36442827
pii: S1341-321X(22)00317-8
doi: 10.1016/j.jiac.2022.11.010
pmc: PMC9699714
pii:
doi:
Substances chimiques
2019-nCoV Vaccine mRNA-1273
EPK39PL4R4
Antibodies, Viral
0
BNT162 Vaccine
0
COVID-19 Vaccines
0
RNA, Messenger
0
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
274-280Informations de copyright
Copyright © 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Blood Adv. 2021 Aug 24;5(16):3053-3061
pubmed: 34387648
Br J Haematol. 2022 Feb;196(4):884-891
pubmed: 34713441
Vaccines (Basel). 2022 Jan 21;10(2):
pubmed: 35214617
Transplant Cell Ther. 2021 Sep;27(9):788-794
pubmed: 34214738
Br J Haematol. 2022 Jun;197(6):709-713
pubmed: 35262920
JAMA Netw Open. 2021 Sep 1;4(9):e2126344
pubmed: 34519770
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
EBioMedicine. 2021 Dec;74:103705
pubmed: 34861491
Cancers (Basel). 2022 Jan 10;14(2):
pubmed: 35053487
Br J Haematol. 2022 Feb;196(3):548-558
pubmed: 34649298
Am J Hematol. 2022 Jan 1;97(1):30-42
pubmed: 34695229
Blood. 2021 Jun 10;137(23):3165-3173
pubmed: 33861303
Haematologica. 2022 Mar 01;107(3):625-634
pubmed: 34320789
Exp Hematol Oncol. 2022 Aug 16;11(1):46
pubmed: 35974381
Blood Cancer Discov. 2021 Sep 13;2(6):577-585
pubmed: 34778798
Int J Hematol. 2022 May;115(5):611-615
pubmed: 35426579
Blood. 2022 Jan 6;139(1):134-137
pubmed: 34818411
Transplant Cell Ther. 2021 Nov;27(11):938.e1-938.e6
pubmed: 34274492
Lancet Haematol. 2021 Mar;8(3):e185-e193
pubmed: 33482113
Emerg Infect Dis. 2021 Jan;27(1):
pubmed: 33058753
Lancet. 2021 Jul 24;398(10297):298-299
pubmed: 34270933
Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1
pubmed: 25529383
Lancet Haematol. 2021 Aug;8(8):e583-e592
pubmed: 34224668
ESMO Open. 2021 Dec;6(6):100283
pubmed: 34634634
Lancet Infect Dis. 2019 Jun;19(6):e200-e212
pubmed: 30744963